Switch theme
Sign up to access all valuation multiples
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
2007
181
LTM Revenue $10.7M
LTM EBITDA -$189M
-$87.9M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Fate Therapeutics has a last 12-month revenue of $10.7M and a last 12-month EBITDA of -$189M.
In the most recent fiscal year, Fate Therapeutics achieved revenue of $13.6M and an EBITDA of -$177M.
Fate Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Fate Therapeutics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $63.5M | $13.6M | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$172M | -$177M | XXX | XXX | XXX |
| EBITDA Margin | -271% | -1295% | XXX | XXX | XXX |
| Net Profit | -$282M | -$161M | XXX | XXX | XXX |
| Net Margin | -443% | -1181% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Fate Therapeutics's stock price is $1.
Fate Therapeutics has current market cap of $106M, and EV of -$87.9M.
See Fate Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$87.9M | $106M | XXX | XXX | XXX | XXX | $-1.61 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Fate Therapeutics has market cap of $106M and EV of -$87.9M.
Fate Therapeutics's trades at -8.2x LTM EV/Revenue multiple, and 0.5x LTM EBITDA.
Analysts estimate Fate Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Fate Therapeutics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | -$87.9M | XXX | XXX | XXX |
| EV/Revenue | -6.4x | XXX | XXX | XXX |
| EV/EBITDA | 0.5x | XXX | XXX | XXX |
| P/E | -0.6x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 0.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpFate Therapeutics's NTM/LTM revenue growth is -66%
Fate Therapeutics's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $1.2M for the same period.
Over next 12 months, Fate Therapeutics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Fate Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Fate Therapeutics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -79% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -1295% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 3% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -1362% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.2M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 544% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 990% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 1535% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Fate Therapeutics acquired XXX companies to date.
Last acquisition by Fate Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Fate Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Fate Therapeutics founded? | Fate Therapeutics was founded in 2007. |
| Where is Fate Therapeutics headquartered? | Fate Therapeutics is headquartered in United States of America. |
| How many employees does Fate Therapeutics have? | As of today, Fate Therapeutics has 181 employees. |
| Who is the CEO of Fate Therapeutics? | Fate Therapeutics's CEO is Dr. Bahram Valamehr, M.B.A.,PhD. |
| Is Fate Therapeutics publicy listed? | Yes, Fate Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Fate Therapeutics? | Fate Therapeutics trades under FATE ticker. |
| When did Fate Therapeutics go public? | Fate Therapeutics went public in 2013. |
| Who are competitors of Fate Therapeutics? | Similar companies to Fate Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Fate Therapeutics? | Fate Therapeutics's current market cap is $106M |
| What is the current revenue of Fate Therapeutics? | Fate Therapeutics's last 12-month revenue is $10.7M. |
| What is the current EBITDA of Fate Therapeutics? | Fate Therapeutics's last 12-month EBITDA is -$189M. |
| What is the current EV/Revenue multiple of Fate Therapeutics? | Current revenue multiple of Fate Therapeutics is -8.2x. |
| What is the current EV/EBITDA multiple of Fate Therapeutics? | Current EBITDA multiple of Fate Therapeutics is 0.5x. |
| What is the current revenue growth of Fate Therapeutics? | Fate Therapeutics revenue growth between 2023 and 2024 was -79%. |
| Is Fate Therapeutics profitable? | Yes, Fate Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
